After Wedbush and William Blair gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Alan Carr assigned a Buy rating to Albireo Pharma today and set a price target of $50.00. The company’s shares closed last Tuesday at $27.01.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.4% and a 42.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Albireo Pharma has an analyst consensus of Strong Buy, with a price target consensus of $48.50, a 78.6% upside from current levels. In a report issued on August 7, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Albireo Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.55 million and GAAP net loss of $31.49 million. In comparison, last year the company earned revenue of $1.25 million and had a GAAP net loss of $16.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
